| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41375-020-0797-X |
| P698 | PubMed publication ID | 32203141 |
| P50 | author | Othman Al-Sawaf | Q47158783 |
| P2093 | author name string | K Fischer | |
| P Cramer | |||
| M Dreyling | |||
| C Schneider | |||
| A M Fink | |||
| C M Wendtner | |||
| M Hallek | |||
| M Ritgen | |||
| S Stilgenbauer | |||
| E Lange | |||
| J Dürig | |||
| E Tausch | |||
| M Kiehl | |||
| J Bahlo | |||
| S Robrecht | |||
| B Eichhorst | |||
| Goede 5th | |||
| J V Tresckow | |||
| P2860 | cites work | Richter transformation of CLL. | Q30249283 |
| IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution | Q33300320 | ||
| Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia | Q33368885 | ||
| Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group | Q33385371 | ||
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
| Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation | Q33417548 | ||
| Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases | Q33682722 | ||
| Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients | Q33903379 | ||
| Richter's transformation in chronic lymphocytic leukemia. | Q34112617 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome | Q34269186 | ||
| Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation | Q34528000 | ||
| Richter's syndrome: biology and therapy | Q36212401 | ||
| Hodgkin's disease variant of Richter's syndrome. Report of eight cases | Q36561320 | ||
| De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience | Q37028638 | ||
| How we treat Richter syndrome | Q37636962 | ||
| First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia | Q38380183 | ||
| Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome | Q40593581 | ||
| First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri | Q40662825 | ||
| Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia | Q42337469 | ||
| Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature | Q44741136 | ||
| Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine | Q44744699 | ||
| Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome | Q46585922 | ||
| The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. | Q51609722 | ||
| Biology and treatment of Richter syndrome. | Q52716941 | ||
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. | Q53061290 | ||
| Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 | ||
| Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome | Q58001002 | ||
| Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales | Q59358067 | ||
| Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | Q64120393 | ||
| Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases | Q70174843 | ||
| Richter's syndrome: a report on 39 patients | Q70505784 | ||
| Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias | Q73181702 | ||
| PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness | Q88676374 | ||
| Richter transformation in the era of novel agents | Q90029192 | ||
| PD-1 is highly expressed by neoplastic B-cells in Richter transformation | Q90359855 | ||
| CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia | Q90647570 | ||
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Q90813107 | ||
| Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial | Q90986748 | ||
| Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | Q92539522 | ||
| Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy | Q92686606 | ||
| Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center | Q92732959 | ||
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| P577 | publication date | 2020-03-17 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials |
| Q94562886 | Chronic lymphocytic leukemia in 2020: a surfeit of riches? | cites work | P2860 |
Search more.